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Background. Myeloproliferative neoplasms are a heterogeneous group of disorders resulting from the abnormal proliferation of one
or more terminal myeloid cells—established complications include thrombosis and haemorrhagic events; however, there is limited
evidence to suggest an association with arterial hypertension. Herein, we report two independent cases of severe hypertension in
JAK2 mutation-positive myeloproliferative neoplasms. Case Presentations. Case 1: a 39-year-old male was referred to our
specialist hypertension unit with high blood pressure (BP) (200/120mmHg), erythromelalgia, and headaches. We recorded
elevated serum creatinine levels (146 μM) and panmyelosis. Bone marrow biopsy confirmed JAK2-mutation-positive
polycythaemia vera. Renal imaging revealed renal artery stenosis. Aspirin, long-acting nifedipine, interferon-alpha 2A, and renal
artery angioplasty were employed in management. BP reached below target levels to an average of 119/88mmHg. Renal
parameters normalised gradually alongside BP. Case 2: a 45-year-old male presented with high BP (208/131mmHg),
acrocyanosis, (vasculitic) skin rashes, and nonhealing ulcers. Fundoscopy showed optic disc blurring in the left eye and full
blood count revealed thrombocytosis. Bone marrow biopsy confirmed JAK2-mutation-positive essential thrombocytosis. No
renal artery stenosis was found. Cardiac output was measured at 5 L/min using an inert gas rebreathing method, providing an
estimated peripheral vascular resistance of 1840 dynes/s/cm5. BP was well-controlled (reaching 130/70mmHg) with CCBs.
Conclusions. These presentations highlight the utility of full blood count analysis in patients with severe hypertension.
Hyperviscosity and constitutive JAK-STAT activation are amongst the proposed pathophysiology linking myeloproliferative
neoplasms and hypertension. Further experimental and clinical research is necessary to identify and understand possible
interactions between BP and myeloproliferative neoplasms.
1. Introduction
Myeloproliferative neoplasms (MPNs) are clonal disorders
arising in the haematopoietic stem cell compartment. MPNs
are mostly diagnosed in the age range of 50 to 60 years; how-
ever, presentations can occur in younger patients, especially
with familial predisposition.
The most common MPN driver gene is Janus kinase 2
(JAK2), a cognate tyrosine kinase for both the erythropoietin
and thrombopoietin receptors. JAK2-mutation-positive
MPNs are associated with a higher rate of vascular complica-
tions. These include thrombotic events and occlusive vascu-
lar diseases. As of yet, there is limited evidence concerning
a potential connection with arterial hypertension. However,
several forms of vascular complications of MPNs have been
described, including pulmonary hypertension [1], portal
hypertension [2], and renovascular hypertension [3].
A retrospective analysis published in 2018 studying 1010
MPN patients in Malaysia demonstrated a significant associ-
ation between JAK2 V617F mutation-positive MPNs and
hypertension [4]. More recently, a study including 10 essen-
tial thrombocytosis patients with venous thrombosis found
that all cases had concurrent arterial hypertension [5]. We
report two cases of acute severe hypertension associated with
JAK2 V617F mutation-positive MPNs. Earlier identification
of MPNs in young, severely hypertensive patients may help
in choosing the right treatment strategy leading to effective
blood pressure (BP) control.
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2. Case Presentations
Summaries of Cases 1 and 2 are displayed in Table 1.
2.1. Case 1 Polycythaemia Vera. A detailed account of Case 1
is displayed in Table 1.
Presentation: A 39-year-old male was referred to our spe-
cialist hypertension unit with a high BP (200/120mmHg),
erythromelalgia, and headaches.
Investigations: We recorded elevated serum creatinine
levels (146μM), panmyelosis with raised haematocrit
(0.534L/L), white blood cell (WBC) (15:8 × 109/L) and platelet
(PLT) (953 × 109/L) counts. Bone marrow biopsy confirmed
JAK2-mutation-positive polycythaemia vera. Renal imaging
revealed renal artery stenosis (Figure 1(a)).
Outcomes and follow-up: Aspirin, nifedipine, interferon-
alpha 2A (cytoreductive therapy—under haematology), and
renal artery angioplasty (Figure 1(b)) were employed in
management. BP reached below target levels to an average
of 119/88mmHg (Figure 2(a)). Renal parameters normalised
gradually alongside BP (Figure 2(b)).
2.2. Case 2 Essential Thrombocytosis. Presentation: A 45-
year-old male presented with high BP (208/131mmHg),
acrocyanosis, vasculitic skin rashes (Figure 3(a)), and non-
healing ulcers (Figure 3(b)).
Investigations: Fundoscopy showed optic disc blurring in
the left eye and full blood count (FBC) revealed thrombocy-
tosis (PLT -953 × 109/L). Bone marrow biopsy confirmed
JAK2-mutation-positive essential thrombocytosis.
Outcomes and follow-up—unlike our Case 1 patient, no
renal artery stenosis was found. BP was well-controlled
(reaching 130/70mmHg) with nifedipine.
3. Discussion
Severely elevated BP (>180/120mmHg) concomitant with
new or progressive target organ dysfunction constitutes
Table 1: Summary of case presentations.
Case 1 Case 2
Initial BP (mmHg) 200/120 208/131
Presenting symptoms
Erythromelalgia, occipital headaches, Vertigo, one episode of
dyspnoea + eye floaters + syncope (1-2 minutes)
Acrocyanosis, Vasculitic skin rashes,
nonhealing toe ulceration
Past medical history Spondylolisthesis Migraines with aura
Family history Father: Vasovagal syncope, myocardial infarction Unremarkable
Social history Ex-smoker 20 units of alcohol per week
Investigations and results
Fundus examination Papilloedema with nasal margin blurring
Arteriovenous nipping with nasal margin
blurring
Urine dipstick Unremarkable Unremarkable
FBC
WBC—15:8 × 109/L; RBC—6:20 × 109/L; Hct -0.534 L/L
PLT −953 × 109/L;
Neutrophil count −12:10 × 109/L
PLT -1096 x109/L
Liver function tests Not indicated
Total bilirubin—38μmol/L; ALT—42U/L;
Gamma GT—94U/L
Electrocardiogram
Sinus rhythm 70 bpm, left axis deviation, biphasic T waves in
leads V5 and V6
Unremarkable
Echocardiogram
Moderate global left ventricular hypertrophy with 1.4 cmwall
thickness
Mild aortic dilatation
Creatinine 146μM 88μM
Renin 107mU/L 80mU/L
Autoimmune screen Negative Negative
Vasculitic skin rash biopsy N/A Unremarkable
Contrast CT abdomen N/A
Enlarged left adrenal gland, lower
abdominal lymphadenopathy
Inert gas rebreathing studies
(clinical research facility)
N/A
Peripheral vascular resistance
-1840 dynes/s/cm5
Interventions
Renal artery angioplasty, aspirin 75mg, intermittent
venesection, interferon-alpha 2A
Aspirin 75mg, long-acting nifedipine
Outcomes
Normalisation of BP and renal parameters, minor side
effects from interferon therapy (decreased libido
and reported thinning of hair), now managed
with single dose of long-acting nifedipine
Normalisation of BP, no adverse outcomes
reported, toe ulceration now healed
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Stenosis
(a) (b)
Figure 1: Case 1—(a) CT renal angiogram showing right renal artery before angioplasty. (b) CT renal angiogram showing right renal artery
after angioplasty.
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Figure 2: Case 1—(a) Changes in BP alongside FBC. (b) Changes in BP alongside renal parameters.
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accelerated hypertension. Current practice overlooks FBC
analysis when evaluating hypertension. Effective BP control
was achieved in Case 1 and 2 with overlapping therapeutic
interventions, suggesting a degree of similarity between the
two pathophysiologies.
Both cases demonstrated good clinical responses to CCBs
(over ACE inhibitor in Case 1), which cause direct vasodilata-
tion through inhibition of calcium ion influx in vascular
smoothmuscle. Thismechanism of actionmight be favourable
in the context of hyperviscosity and elevated vascular resis-
tance, as proposed in Figure 4. In Case 2, peripheral vascular
resistance (PVR)was calculated fromcardiac output and stroke
volume measurements using an inert gas rebreathing method
(Innocor) [6]. This provided an estimate of 1840 dynes/s/cm5,
considerably exceeding the normal range of 900-1440
dynes/s/cm5, and that usually is seen in hypertension.
Raised PVR together with nonhealing ulceration could
strongly suggest that vasoconstriction and microvascular rar-
efaction underly the hypotheses. A number of mechanisms
may explain this in patients with essential thrombocytosis
and polycythaemia vera. Increased haematocrit and platelet
aggregation lead to whole blood hyperviscosity, which can
add to both, the humoral and haemodynamic changes.
Increased haematocrit increases the probability of adhesive
wall collisions mediated by platelets. Platelets synthesise
and discharge haemostatic mediators including thrombox-
ane A2, PGF2 alpha, and serotonin, all of which are potent
vasoconstrictors. These may lead to the activation of endothe-
lial cells, resulting in increased expression of adhesion mole-
cules and secretion of thrombogenic and angiogenic peptides
from local inflammatory cells and procoagulant factors
including von Willebrand factor (vWF). Endothelial injury/-
dysfunction has been postulated to be one of the mechanisms
by which raised haematocrit predisposes to thrombotic com-
plications [7]. Flow-mediated dilation (FMD), a marker for
endothelial function, was found to be reduced in a small study
in MPN patients, demonstrating the role of endothelium
dysfunction [8]. Endothelial damage further leads to arterial
insufficiency and capillary rarefaction—particularly in the
microcirculation where endothelial dysfunction is greatest.
This leads to a vicious cycle of endothelial damage, account-
ing for the chronic ulceration displayed by our patient.
The haemodynamic effects of ACE inhibitors and CCBs
are known to differ. Whilst ACE inhibitors antagonise the
renin-angiotensin system and reduce sympathetic output,
CCBsmediate dilatation of large conduit and resistance arter-
ies. These differences might explain the preferential respon-
siveness exhibited in both cases. However, the true relevance
for MPN patients remains unclear, particularly as there is
conflicting evidence to demonstrate a direct correlation
between blood viscosity and pressure in normotensive and
hypertensive subjects [9, 10].
Case 1 indicates an additional renovascular component
to the patient’s presentation. Several factors are likely to have
(a) (b)
Figure 3: Case 2—(a) Vasculitic skin rashes. (b) Nonhealing ulcers.
Calculation of peripheral vascular resistance
Peripheral vascular resistance estimation formula:
Calculation using patient values indexed to body surface area:
Proposed mechanism
MPNs: clonal proliferation
of bone marrow stem cells
– excess production
Increased vessel
resistance by
Poiseuille’s Law
R = vessel
resistance
𝜂 = blood viscosity
L = vessel length
r = vessel radius
Peripheral vascular resistance = mean arterial pressure × (80/cardiac output)
Peripheral vascular resistance = 115 × (80/5)
(dynes/s/cm5) (mmHg) (L/min)
Peripheral vascular resistance = 1840 (↑↑ - normal range: 900–1440)
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Figure 4: Case 2—Vessel resistance calculation and suggested mechanism for increase. Elevated peripheral vascular resistance with
nonhealing ulcers could indicate vasoconstriction and microvascular rarefaction.
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contributed to the stenotic lesion including raised haemato-
crit, dysregulated coagulation, and abnormal vascular endo-
thelial functions. These mechanisms have been discussed by
Tamura et al. in a previous description of two patients with
hypertension secondary to renal artery stenosis with JAK2
V617F-positive MPNs, both of whom were successfully
managed with angioplasty [11]. The utility of angioplasty is
considered highly dependent on the pathogenesis of renal
artery stenosis. In patients with atherosclerotic stenosis,
angioplasty demonstrates no significant advantage over med-
ical management in the regulation of BP [12]. In comparison,
MPN-associated renovascular hypertension responds well to
this intervention. The greater extent of unresolved ischaemia
in atherosclerotic pathophysiology is thought to account for
this difference, meaning that MPN patients with coexistent
renovascular atherosclerosis might receive limited benefit
from renal angioplasty [13]. However, the fact that both
patients responded to vasodilatory medications could imply
that the stenosis is a bystander or indeed a by-product here
rather than the main driver for acute rise in blood pressure.
Constitutive JAK-STAT activation has been suggested to
increase the activation of platelets, and recruitment of plate-
lets and leukocytes in conjunction with accelerated vascular
cell hyperplasia [7]. Furthermore, the activated JAK-STAT
pathway is known to contribute to local synthesis of Angio-
tensin II (Ang II), and in turn, the progression of Ang II-
dependent hypertension [14]. Ang II-activated JAK2 prompts
phosphorylation of Arhgef1 in vascular smooth muscle cells
[15]; consequently, Arhgef1 stimulates the RhoA-Rho kinase
axis, resulting in BP augmentation. In support of these find-
ings, pharmacological inhibition of JAK2 has been shown to
reduce hypertension in Ang-II infused animal models [16,
17]. JAK-STAT signalling has also been implicated in renal
injury, with hyperglycaemia inducing the pathway via Ang
II in glomerular mesangial cells [18]. Consistent with this
observation, JAK2 inhibition in ratmodels prevented protein-
uria and hypertension in streptozotocin-induced diabetic
nephropathy [19], as well as ameliorating renal ischaemia-
reperfusion injury [20].
Further study of the relationship between haemorheol-
ogy, haemodynamics, and the role of endothelial dysfunction
in MPNs is needed.
4. Conclusion
This report highlights the importance of simple FBC analysis
in severe hypertension and the potential therapeutic role of
CCBs. Increased platelet counts, hyperviscosity, rarefaction
of vasculature, and resultant release of vasoconstrictive medi-
ators are amongst the proposed pathophysiologies linking
MPNs and hypertension. Associated vascular complications
like arterial and venous thrombosis may add to the burden
of vascular damage. Further experimental and clinical evi-
dence is required to identify mechanisms of interaction
between JAK2 function and BP.
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